Project Grant R03CA292965
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$168K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
This Project Grant award, with a total funding amount of $684,877, was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award will support a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer (NMIBC) patients to identify novel therapeutic targets for overcoming resistance to the standard-of-care treatment, Bacillus Calmette-Guerin (BCG). The research will utilize single-cell and spatial...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $514,582 to the University of North Carolina at Chapel Hill from March 1, 2025 to February 28, 2030 to conduct research on targeting APOBEC3-induced squamous differentiation in bladder cancer. The key focus of the research is to better understand the role of APOBEC3 enzymes in bladder cancer initiation and progression, particularly their impact on promoting squamous...
The National Cancer Institute awarded a $269,154 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of Chicago to characterize the genome-wide 5-hydroxymethylcytosine (5hmC) landscape of healthy urine and develop biomarkers for localized bladder cancer. The project aims to: 1) identify sources of variation, characterize the genomic and epigenomic 5hmC landscape, and infer the tissue-of-origin of cell-free DNA in healthy urine, and 2) develop diagnostic and predictive...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $550,166 to the University of Rochester to investigate mechanisms of bladder inflammation and radiation-induced injury, and develop a urine-based biomarker to predict and monitor radiation cystitis (RC) in prostate cancer patients receiving radiotherapy. The research aims to characterize the role of the renin-angiotensin system and inflammation in bladder injury, determine...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $543,221 to the Albert Einstein College of Medicine in Bronx, NY to conduct research targeting lineage plasticity to inhibit the progression of basal-like breast cancer (BLBC). The primary goals are to: 1) Define the key de-differentiated cells required for BLBC progression and explore strategies to target these cells for cancer interception, and 2) Elucidate the molecular...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
The National Cancer Institute (NCI) awarded a 5-year, $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine in Bronx, NY, effective January 1, 2025. The grant supports research to investigate the non-autonomous role of androgen signaling in prostate tumorigenesis, with a focus on understanding how stromal androgen receptor (AR) signaling in GLI1-lineage cells promotes prostate epithelial oncogenesis, tumor initiation, progression, and the...
This federal Project Grant award, with ID R37CA300540, was provided by the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research program) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The $564,414 award, effective from April 1, 2025 to March 31, 2030, supports research with two key objectives: 1) Developing and validating a predictive model using electronic health record data to accurately identify individuals at high risk for...